Table 2

Patients enrolled in protocol, with clinical outcome

Patient IDGenderGroupStageNo. of vaccinesReason off protocolTime to progression (yr)Site of progressionFollow-upa (yr)At last follow-up
Alive?NED?
1101M1III4Progression0.5Multidistant0.6NN
1102M1III74.6YY
1103F2IIB74.5YY
1104F2IV71.7Skin4.6YY
1105F1IIB72.5Nodes4.4YY
1106F2III74.1YY
1107M1III2Progression0.2Intransit1.6NN
1108M2III73.6YY
1109M2IIIb2Progression0.2Lung0.4NN
1110M3III71.8Nodes3.0YY
1111F3III6Other cancer0.9YY
1112M6III73.1YY
1113M5III6Noncompliance2.6YY
1114M4IV4Progression0.4Nodes1.2NN
1115M6III4Progr or MIc0.5Not evaluable0.5NN
1116F6III3Progression0.3Intransit0.9YN
1117M3III72.4YY
1118M5IV72.1YY
1119F5IV71.5Liver1.9YY
1120F4IIB71.6YY
1121F5III4Progression0.5Intransit1.4YN
1122F3III6Adverse event1.5YY
  • a Mean follow-up, 2.3 years; median follow-up, 2.0 years; median follow-up of living patients, 2.6 years. NED, no evidence of disease.

  • b This patient had minimal measurable disease at protocol entry.

  • c Progr or MI, progression or myocardial infarction.